The PubMed record documents a 2026 article in Bioorganic Chemistry titled “Discovery of Schiff base‑triazole‑pleuromutilin conjugates as broad‑spectrum antibacterial agents with potent anti‑MRSA activity.” The title identifies a new chemical series — Schiff base‑triazole‑pleuromutilin conjugates — and claims both broad‑spectrum antibacterial activity and potent activity against methicillin‑resistant Staphylococcus aureus (MRSA).
The content available on PubMed for this item is limited to bibliographic metadata (title, authors, affiliations, journal citation, PMID, DOI) and links to the publisher. The record as presented here does not include the article abstract, experimental methods, numerical results, or detailed conclusions. Readers interested in specific pharmacologic or microbiologic data must consult the full text via the linked Elsevier Science options or institutional access.
The article is authored by Cai‑Xiang Zhang, Shaoting Chen, Hongdong Liu, Ziying Li, Hazrat Bilal, Hong Liang, Yanghan Liu, and Zhen‑Feng Chen. Affiliations list multiple research units at Guangxi Normal University and associated laboratories in Guilin, Guangxi, PR China, including key laboratories for chemistry and molecular engineering of medicinal resources and a laboratory for multimodal biomarkers and precision diagnosis.
Bibliographic identifiers provided by the PubMed entry include PubMed ID 42208466 and DOI 10.1016/j.bioorg.2026.110029. The article was published online on 25 May 2026 and is associated with the September 5, 2026 issue (Volume 179:110029) of Bioorganic Chemistry.
According to the article title, the focus is on conjugates that link Schiff base motifs, triazole units, and the pleuromutilin scaffold. The title reports two primary claims:
Beyond the title, the PubMed record shown here does not provide chemical structures, synthetic routes, structure–activity relationships, minimum inhibitory concentration (MIC) data, spectrum of organisms tested, or comparative potency versus reference antibiotics. Such experimental details are not available in the source content provided.
The PubMed entry includes a link to Elsevier Science full‑text options. Access to the full article will be required to review the experimental design (in vitro and/or in vivo assays), specific bacterial strains tested, quantitative antimicrobial results, toxicity or ADME data, and any discussion of mechanism of action. The PubMed abstract field and full methodological details were not included in the recorded excerpt used here.
Reported in this PubMed record:
Not reported in this PubMed excerpt (details not available in the source):
Because these items are absent from the PubMed content provided here, they are explicitly not asserted in this summary.
If validated by the full manuscript, the reported identification of Schiff base‑triazole‑pleuromutilin conjugates with broad‑spectrum activity and potency against MRSA could be of interest to medicinal chemists and infectious disease researchers focused on new antibacterial scaffolds. Pleuromutilin derivatives are an established class with clinical precedents, and hybridization with triazole and Schiff base functionalities represents a medicinal chemistry strategy to modulate spectrum, potency, and pharmacologic properties.
However, evaluation of clinical relevance requires access to the underlying data: spectrum of activity across Gram‑positive and Gram‑negative pathogens, MIC distributions, resistance profiling, cytotoxicity and selectivity indices, and any in vivo efficacy or pharmacokinetic findings. These are not available in the PubMed record excerpt and must be confirmed in the full article.
This rewritten clinical brief is constrained to the information present in the PubMed record. It does not reproduce or infer experimental results beyond the article title. To appraise the validity and potential translational value of the reported conjugates, readers should obtain and review the full text for:
Accessing the Elsevier Science full‑text link via the PubMed page or institutional subscriptions will provide the complete data needed to assess the study’s scientific and clinical significance.